U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula 2C20H37O7S.Ca
Molecular Weight 883.215
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOCUSATE CALCIUM

SMILES

[Ca++].CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O.CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O

InChI

InChIKey=DWKPZOZZBLWFJX-UHFFFAOYSA-L
InChI=1S/2C20H38O7S.Ca/c2*1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h2*16-18H,5-15H2,1-4H3,(H,23,24,25);/q;;+2/p-2

HIDE SMILES / InChI
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Study of the factors affecting the extraction of soybean protein by reverse micelles.
2010-02
Physico-chemical investigation of nanostructures in liquid phases: nickel chloride ionic clusters confined in sodium bis(2-ethylhexyl) sulfosuccinate reverse micelles.
2009-08-01
Complexes between high charge density cationic polyelectrolytes and anionic single- and double-tail surfactants.
2009-05-21
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. II: Effect of the surfactant.
2009-05-14
Modulation of excited-state proton-transfer reactions of 7-hydroxy-4-methylcoumarin in ionic and nonionic reverse micelles.
2009-05-14
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. I. Effect of the hemicyanines' structure.
2009-04-02
Molecular dynamics simulations of AOT-water/formamide reverse micelles: structural and dynamical properties.
2008-12-28
Modulation of dynamics and reactivity of water in reverse micelles of mixed surfactants.
2008-10-16
Fine control over the morphology and structure of mesoporous silica nanomaterials by a dual-templating approach.
2008-10-07
Fourier transform infrared spectroscopy of azide and cyanate ion pairs in AOT reverse micelles.
2008-07-14
Fluorescence anisotropy of ionic probes in AOT reverse micelles: influence of water droplet size and electrostatic interactions on probe dynamics.
2008-06-19
Design and control of patterns in reaction-diffusion systems.
2008-06
Optical sensor of anionic surfactants using solid-phase extraction with a lactone-form rhodamine B membrane.
2008-06
Synthesis and characterization of one-dimensional CdSe by a novel reverse micelle assisted hydrothermal method.
2008-04-15
P450cam biocatalysis in surfactant-stabilized two-phase emulsions.
2008-04-15
The spectrophotometric study of the binding of vitamin E to water + dimethyl sulfoxide and water + diethyl sulfoxide containing reversed micelles.
2008-04-02
Micellization and synergistic interaction of binary surfactant mixtures based on sodium nonylphenol polyoxyethylene ether sulfate.
2008-02-15
On the investigation of the bilayer functionalities of 1,2-di-oleoyl-sn-glycero-3-phosphatidylcholine (DOPC) large unilamellar vesicles using cationic hemicyanines as optical probes: a wavelength-selective fluorescence approach.
2008-01-01
Kinetics of the photosensitized oxidation of chymotrypsin in different media.
2008-01
Ultrafast energy transfer in water-AOT reverse micelles.
2007-12-27
A novel composite: layered double hydroxides encapsulated in vesicles.
2007-12-20
Improvement in extraction and catalytic activity of Mucor javanicus lipase by modification of AOT reverse micelle.
2007-11
Site-specific hydration status of an amphipathic peptide in AOT reverse micelles.
2007-10-23
On the possibility that cyclodextrins' chiral cavities can be available on AOT n-heptane reverse micelles. A UV-visible and induced circular dichroism study.
2007-09-13
The effect of changing the microstructure of a microemulsion on chemical reactivity.
2007-09-11
Ultrasound induced formation of paraffin emulsion droplets as template for the preparation of porous zirconia.
2007-09
Compartmentalization of reactants in different regions of sodium 1,4-bis(2-ethylhexyl)sulfosuccinate/heptane/water reverse micelles and its influence on bimolecular electron-transfer kinetics.
2007-08-02
Study of confined 5-aza[5]helicene in ytterbium(III) bis(2-ethylhexyl) sulfosuccinate reversed micelles.
2007-04-26
Iron dissolution in aqueous AOT solution.
2007-02-15
The dispersion-stability diagram of boehmite nanoparticles in aqueous AOT solutions.
2007-02-15
Thiol-frozen shape evolution of triangular silver nanoplates.
2007-02-13
Atomic force microscopy images of lyotropic lamellar phases.
2007-02-07
Dye-sensitized solar cells based on nanocrystalline titania electrodes made at various sintering temperatures.
2007-02
[Chemotaxis as a method for testing of the biological effects of silver nanoparticles].
2006-11-30
Comparative study of the photophysical behavior of fisetin in homogeneous media and in anionic and cationic reverse micelles media.
2006-11-23
Hydrogen bond lifetime dynamics at the interface of a surfactant monolayer.
2006-11-23
An insight into the mechanism of protein separation by colloidal gas aphrons (CGA) generated from ionic surfactants.
2006-11-07
Simultaneous determination of natural and synthetic estrogens by EKC using a novel microemulsion.
2006-11
Spectrofluorimetric determination of tin in canned foods.
2006-10-11
Nucleation and growth characteristics of a binary low-mass organogel.
2006-08-15
Sensing behaviors of polypyrrole nanotubes prepared in reverse microemulsions: effects of transducer size and transduction mechanism.
2006-07-27
Tuning the cooperativity of the helix-coil transition by aqueous reverse micelles.
2006-06-22
Electrochemical extraction of proteins by reverse micelle formation.
2006-06-20
Efficient gene transfection using chitosan-alginate core-shell nanoparticles.
2006
Real structure of formamide entrapped by AOT nonaqueous reverse micelles: FT-IR and 1H NMR studies.
2005-11-10
Investigation of micelle formation by fluorescence correlation spectroscopy.
2005-07-14
Vibrational relaxation of azide in formamide reverse micelles.
2005-07-07
On the temperature percolation in a w/o microemulsion in the presence of organic derivatives of chalcogens.
2005-05-19
Reverse micelles dissolved in supercritical xenon: an NMR spectroscopic study.
2005-03-03
Monolayer of aerosol-OT surfactants adsorbed at the air/water interface: an atomistic computer simulation study.
2005-01-13
Patents

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Constipation: Oral: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day. Rectal: 200 to 283 mg rectally administered as an enema once or twice. Alternative: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day. Usual Pediatric Dose for Constipation: Oral: less than 3 years: 10 to 40 mg (docusate sodium) orally divided in 1 to 4 doses. 3 to 6 years: 20 to 60 mg (docusate sodium) orally divided in 1 to 4 doses. 6 to 12 years: 40 to 150 mg (docusate sodium) orally divided in 1 to 4 doses. greater than 12 years: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day. Rectal: 3 to 18 years: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day. Alternative: 200 to 283 mg rectally administered as an enema once daily as needed for constipation.
Route of Administration: Other
It was evaluated the efficacy and toxicity of docusate against herpes simplex viruses (HSV). Docusate was effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2 with EC(90-100) (effective concentration giving 90-100% virus yield reduction) of approximately 0.005% (w/v). The cytotoxicity profiles of docusate were time- and dose-dependent and thus associated with the frequency of use. Kinetics of inactivation examined by pre-mixing virus and drug in a time-course experiment demonstrated that docusate could reach its EC(90-100) within 30 min.
Name Type Language
DOCUSATE CALCIUM [MI]
Preferred Name English
DOCUSATE CALCIUM
MART.   MI   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
DOCUSATE CALCIUM [USAN]
Common Name English
1,4-Bis(2-ethylhexyl) sulfosuccinate, calcium salt
Common Name English
DOCUSATE CALCIUM [MART.]
Common Name English
BUTANEDIOIC ACID, SULFO-, 1,4-BIS(2-ETHYLHEXYL) ESTER, CALCIUM SALT
Common Name English
DIOCTYL CALCIUM SULFOSUCCINATE
Systematic Name English
Docusate calcium [WHO-DD]
Common Name English
DOCUSATE CALCIUM [USP MONOGRAPH]
Common Name English
SURFAK
Brand Name English
DOCUSATE CALCIUM [VANDF]
Common Name English
DOCUSATE CALCIUM [USP-RS]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29699
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
Code System Code Type Description
EVMPD
SUB01806MIG
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL1477036
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
PUBCHEM
31407
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
MERCK INDEX
m4715
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1224700
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
FDA UNII
6K7YS503HC
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
NCI_THESAURUS
C28999
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
CAS
128-49-4
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
SMS_ID
100000087522
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-889-8
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
RXCUI
82001
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY RxNorm
DRUG BANK
DBSALT001505
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID2044212
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY
DAILYMED
6K7YS503HC
Created by admin on Mon Mar 31 21:26:22 GMT 2025 , Edited by admin on Mon Mar 31 21:26:22 GMT 2025
PRIMARY